Table 2.

Clinical progress and outcome

	IV midazolam	IM midazolam	Buccal midazolam
Number of children	13	12	8
Blantyre coma score on admission	3 (0–5)	2 (0–5)	3 (0–5)
Blood transfusion (n)	1 (8%)	2 (17%)	0 (0%)
Number of convulsions after admission	3 (1–uncountable)	2 (1–uncountable)	1 (1–3)
Patients with convulsions controlled with a single dose of midazolam	13 (100%)	9 (75%)	5 (63%)
Latency (time from initial midazolam administration to convulsion control) (min)	2 (1–6)	5 (1–5)	3.5 (1–5)
Patients with recurrence convulsions after midazolam*	6 (46%)	2 (22%)	0 (0%)
Patients requiring additional anticonvulsants:
Paraldehyde	3 (23%)	1 (8%)	0 (0%)
Phenobarbital	4 (31%)	4 (33%)	3 (38%)
Phenytoin	3 (23%)	3 (25%)	3 (38%)
Thiopental	1 (8%)	0 (0%)	0 (0%)
Patients with respiratory depression after midazolam	1 (8%)	1 (8%)	2 (25%)*
Deaths	0 (0%)	1 (8%)	3 (38%)

Values are expressed as number (percentage) or number (range).

^*Statistically significantly different from the IV MDZ group (P = 0.029).